Celgene's drug Otezla (apremilast ... Xeljanz in early 2015 for moderate-to-severe chronic plaque psoriasis. Another anticipated new competitor is Lilly. Just last month the firm unveiled strong ...

and BMS says it now plans to launch the new drug later this month, aiming to mount a challenge to Amgen's $2.3 billion oral psoriasis therapy Otezla (apremilast). BMS has previously said it ...

Drugmakers have raised the list prices of more than 800 prescription drugs — ranging from blood pressure medications to cancer treatments — by a median of 4% at the start of this year, The Wall Street ...

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships ...

Danish pharmaceutical company Novo Nordisk’s revolutionary Type 2 diabetes medication Ozempic, obesity injection Wegovy, and diabetes pill ... disorder, Otezla to treat plaque psoriasis, and ...

Its key products include anti-inflammation drug Stelara ... In the U.S., Amgen recently launched Otezla for treating plaque psoriasis in children ages 6 and older. Argus has a “buy” rating ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

made by Bristol Myers Squibb Co., and Amgen Inc.’s psoriasis drug Otezla. Pfizer said the negotiation process discourages the development of new medicines, but that it will work to protect ...